Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Is Hydroxychloroquine a Possible Post-Exposure Prophylaxis Drug to Limit the Transmission to Health Care Workers Exposed to COVID19?

Pagliano et al., Clin. Infect. Dis., 2020 Mar 24, doi:10.1093/cid/ciaa320
Mar 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19hcq.org
CQ and HCQ inhibit replication at early stages of infection, no similar effect reported for other drugs which are only able to interfere after cell infection. Large volume of existing data on safety. (8/23: we corrected the classification of this study)
Pagliano et al., 24 Mar 2020, peer-reviewed, 5 authors.
This PaperHCQAll
2019 Novel Coronavirus Is Undergoing Active Recombination
Huiguang Yi
Clinical Infectious Diseases, doi:10.1093/cid/ciaa219
www. maths.otago.ac.nz/~dbryant/software/phimanual. pdf 9. Jiang X, Robertson DL. nCoV's relationship to bat coronaviruses and recombination signals (no snakes)-no evidence the 2019-nCoV lineage is recombinant. 2020.
References
Barnard, Day, Bailey, Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice, Antivir Chem Chemother
De Wilde, Jochmans, Posthuma, Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture, Antimicrob Agents Chemother
Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases?, Lancet Infect Dis
Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases?, Lancet Infect Dis
Schwartz, King, Protecting health care workers during the COVID-19 coronavirus outbreak: lessons from Taiwan's SARS response
Yao, Ye, Zhang, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Yao, Ye, Zhang, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis
{ 'DOI': '10.1093/cid/ciaa320', 'ISSN': ['1058-4838', '1537-6591'], 'URL': 'http://dx.doi.org/10.1093/cid/ciaa320', 'author': [ { 'affiliation': [ { 'name': 'Department of Medicine and Surgery, University of Salerno, ' 'Baronissi, Italy'}], 'family': 'Pagliano', 'given': 'Pasquale', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'Department of Medicine and Surgery, University of Salerno, ' 'Baronissi, Italy'}], 'family': 'Piazza', 'given': 'Ornella', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Medicine and Surgery, University of Salerno, ' 'Baronissi, Italy'}], 'family': 'De Caro', 'given': 'Francesco', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Service of Infectious Diseases, Cardarelli Hospital, Naples, ' 'Italy'}], 'family': 'Ascione', 'given': 'Tiziana', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Medicine and Surgery, University of Salerno, ' 'Baronissi, Italy'}], 'family': 'Filippelli', 'given': 'Amelia', 'sequence': 'additional'}], 'container-title': 'Clinical Infectious Diseases', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2020, 3, 21]], 'date-time': '2020-03-21T12:10:12Z', 'timestamp': 1584792612000}, 'deposited': { 'date-parts': [[2021, 3, 5]], 'date-time': '2021-03-05T13:05:03Z', 'timestamp': 1614949503000}, 'indexed': {'date-parts': [[2024, 2, 27]], 'date-time': '2024-02-27T14:23:16Z', 'timestamp': 1709043796329}, 'is-referenced-by-count': 16, 'issue': '15', 'issued': {'date-parts': [[2020, 3, 24]]}, 'journal-issue': { 'issue': '15', 'published-online': {'date-parts': [[2020, 3, 24]]}, 'published-print': {'date-parts': [[2020, 7, 28]]}}, 'language': 'en', 'license': [ { 'URL': 'https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model', 'content-version': 'vor', 'delay-in-days': 0, 'start': { 'date-parts': [[2020, 3, 24]], 'date-time': '2020-03-24T00:00:00Z', 'timestamp': 1585008000000}}], 'link': [ { 'URL': 'http://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciaa320/33040019/ciaa320.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/cid/article-pdf/71/15/887/33538075/ciaa320.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'syndication'}, { 'URL': 'http://academic.oup.com/cid/article-pdf/71/15/887/33538075/ciaa320.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '286', 'original-title': [], 'page': '887-888', 'prefix': '10.1093', 'published': {'date-parts': [[2020, 3, 24]]}, 'published-online': {'date-parts': [[2020, 3, 24]]}, 'published-other': {'date-parts': [[2020, 8, 1]]}, 'published-print': {'date-parts': [[2020, 7, 28]]}, 'publisher': 'Oxford University Press (OUP)', 'reference': [ { 'DOI': '10.1093/cid/ciaa237', 'article-title': 'In vitro antiviral activity and projection of optimized dosing design ' 'of hydroxychloroquine for the treatment of severe acute respiratory ' 'syndrome coronavirus 2 (SARS-CoV-2) [manuscript published online ahead ' 'of print 9 March 2020]', 'author': 'Yao', 'doi-asserted-by': 'crossref', 'first-page': '732', 'journal-title': 'Clin Infect Dis', 'key': '2020072806270834900_CIT0001', 'volume': '71', 'year': '2020'}, { 'DOI': '10.1093/cid/ciaa255', 'article-title': 'Protecting health care workers during the COVID-19 coronavirus ' 'outbreak: lessons from Taiwan’s SARS response [manuscript published ' 'online ahead of print 12 March 2020]', 'author': 'Schwartz', 'doi-asserted-by': 'crossref', 'first-page': '858', 'journal-title': 'Clin Infect Dis', 'key': '2020072806270834900_CIT0002', 'volume': '71', 'year': '2020'}, { 'DOI': '10.1016/S1473-3099(03)00806-5', 'article-title': 'Effects of chloroquine on viral infections: an old drug against today’s ' 'diseases?', 'author': 'Savarino', 'doi-asserted-by': 'crossref', 'first-page': '722', 'journal-title': 'Lancet Infect Dis', 'key': '2020072806270834900_CIT0003', 'volume': '3', 'year': '2003'}, { 'DOI': '10.1038/s41598-017-15467-6', 'article-title': 'Repurposing of the anti-malaria drug chloroquine for Zika virus ' 'treatment and prophylaxis', 'author': 'Shiryaev', 'doi-asserted-by': 'crossref', 'first-page': '15771', 'journal-title': 'Sci Rep', 'key': '2020072806270834900_CIT0004', 'volume': '7', 'year': '2017'}, { 'DOI': '10.1186/1743-422X-2-69', 'article-title': 'Chloroquine is a potent inhibitor of SARS coronavirus infection and ' 'spread', 'author': 'Vincent', 'doi-asserted-by': 'crossref', 'first-page': '69', 'journal-title': 'Virol J', 'key': '2020072806270834900_CIT0005', 'volume': '2', 'year': '2005'}, { 'article-title': 'Clinical trial analysis of 2019-nCoV therapy registered in China ' '[manuscript published online ahead of print 28 February 2020]', 'author': 'Zhang', 'journal-title': 'J Med Virol', 'key': '2020072806270834900_CIT0006', 'year': '2020'}], 'reference-count': 6, 'references-count': 6, 'relation': {}, 'resource': {'primary': {'URL': 'https://academic.oup.com/cid/article/71/15/887/5811417'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': [], 'subtitle': [], 'title': 'Is Hydroxychloroquine a Possible Postexposure Prophylaxis Drug to Limit the Transmission to ' 'Healthcare Workers Exposed to Coronavirus Disease 2019?', 'type': 'journal-article', 'volume': '71'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit